ACTA1 and pulmonary fibrosis: Sitagliptin treatment enhanced the expression of CD31 and lessened the expression of α-SMA in LPS-induced pulmonary fibrosis blood vessels and surrounding tissues in mice, and EndMT was further aggravated by the addition of miR-23b-3p agomir (Fig. 6b).